A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC

This is a Phase II, open-labeled, single-arm, study of neoadjuvant BL-B01D1in combination with Almonertinib followed by adjuvant Almonertinib for the treatment of Patients with EGFR-Mutation Positive Stage II-IIIB Resectable Non-Small Cell Lung Cancer.

Trial Details

NCT ID
NCT06951464
Phase
PHASE2
Sponsor
Sichuan University
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • BL-B01D1
  • Almonertinib
Locations (sample)
  • Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

  • Voluntarily sign the informed consent form and comply with the study protocol requirements.
  • Male or female, Age ≥18 years and ≤75 years at the time of signing the informed consent form.
  • Diagnosed with stage II-IIIB (according to Version 8 of TNM staging) EGFR-sensitive mutation-positive non-small cell lung cancer (NSCLC) with feasi…
  • Adequate pulmonary function to tolerate surgery.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →